Mast cells play a significant role in allergic diseases and, along with macrophages, are important in the inflammatory process. Upon activation, mast cells degranulate and release mediators via different mechanisms in response to various stimuli. Allergic reactions are induced mainly by preformed mast cell mediators including histamine, tryptase, and chymase. Spikes in tryptase titers can be considered a marker of anaphylaxis [1, 2] , whereas increments in basal serum tryptase (BST) levels can be considered a marker of increased mast cell burden, as in mastocytosis [3] , or of circumscribed inflammation, as in coronary atherosclerosis. In the follow-up of patients with previous acute coronary syndrome (ACS), we found that persisting elevated BST levels correlated with an increased risk of major adverse cardiovascular events (MACE) [4, 5] . In other cases, high BST levels were shown to be biomarkers for the risk of severe allergic reactions to hymenoptera venom [6] . Given the heterogeneity of situations characterized by high BST levels, we aimed to detect specific values to formulate the prognosis or diagnosis of various clinical conditions.
We compared BST ranges in 2 clinical disorders. One population comprised patients with hymenoptera venom allergy (HVA) and a history of Mueller grade III and IV anaphylactic reactions [7] . The second population comprised patients with a history of ACS that we had previously described in 2 studies and now includes 9 new patients [8, 5] . The statistical evaluation was based on a descriptive analysis, followed by inference using the Fisher exact test for categorical variables. We also performed the t test for continuous variables and logistic regression followed by ROC analysis to dichotomize continuous variables with the aim of determining possible cut-off values.
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The optimal cut-off was set at 7.0 ng/mL, with a 54% positive predictive value (95%CI, 39%-68%), 84% negative predictive value (95%CI, 77%-84%), 50% sensitivity (95% CI, 36%-64%), and 86% specificity (95%CI, 79%-91%).
In each of the 2 study populations, we found that in patients with the most severe clinical conditions, the tryptase level was approximately 7.0 ng/mL. The persistence of high BST levels suggests the possibility of monitoring these levels as a long-term marker of possible subsequent deterioration in patients with impaired heart conditions (eg, coronary atherosclerotic lesions). While the role of mast cells in ischemic heart disease can be more readily accepted, given the demonstration of their accumulation at the site of coronary atheromatous erosion [10] , the reason for their proliferation in patients who go on to develop HVA is more difficult to explain, except for those cases that go on to develop systemic mastocytosis and mast cell activation syndrome. Our results seem to indicate that, despite the fact that HVA and ACS are completely different clinical conditions, they are characterized by a similar increase in tryptase levels, possibly in relation to an increase in concentrations of mast cells resident in vascular atherosclerotic lesions. The final severity of clinical features will then depend on other factors, such as the presence of specific hymenoptera venom IgE or previous extensive cardiovascular involvement. Tryptase is an important marker of vascular inflammatory involvement that could be useful in clinical practice for identifying patients Component-resolved diagnosis (CRD) has modified the accuracy of the diagnosis of respiratory allergy and prescription of specific immunotherapy (SIT) [1, 2] . CRD has demonstrated the presence of minor allergens in SIT extracts and their role in some adverse effects of SIT [2, 3] . Its association with the efficacy of SIT has not been tested. Our objective was to assess the possible association between the clinical efficacy of a Dermatophagoides pteronyssinus SIT extract and sensitization to mite allergens in a group of patients with respiratory allergy induced by house dust mite (HDM).
We performed a retrospective post hoc analysis of the efficacy and safety of a SIT study previously carried out by our group [4, 5] with currently available HDM-based CRD. Our previous study was a prospective, phase 4, randomized, controlled study with a 5-year follow-up period. A total of 142 patients aged 5-45 years with HDM-induced respiratory allergy received SIT extract (Pangramin Depot UM, ALKAbelló, 10 UB/mL; Der p 1, 4 µg/mL; and Der p 2, 2 µg/mL) for at least 3 years. Adherence to SIT was good. Clinical evaluations and blood samples obtained before initiation of SIT were available for 84 patients. Differences in baseline characteristics between good and poor adherers were ruled out [5] . Efficacy and safety data have been published elsewhere [4, 5] 
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